comprehensive
Previous article:
How one medical school became remarkably diverse
Next article: Drugmakers bet big on mRNA for cancer. Why's Biden going in?
Next article: Drugmakers bet big on mRNA for cancer. Why's Biden going in?
knowledge
hotspot
-
Susan Tousi leaves Illumina to head cancer liquid biopsy startup
2025-09-28 02:30 -
Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi
2025-09-28 02:12 -
J&J to buy cancer drug developer Ambrx Biopharma
2025-09-28 01:49 -
UCB departs biotech trade group BIO
2025-09-28 01:44 -
Study: Spinal cord stimulation helps patients with paralysis walk again
2025-09-28 01:17 -
Antibiotic resistance and the global rise in human conflict
2025-09-28 00:18